| TAH Drug Code | OMET1 |
|---|---|
| Indications | Attention-deficit hyperactivity disorder; narcolepsy. |
| Dosing | Children >= 6 years: Initially 5 mg QD or BID with gradual increments of 5-10 mg weekly. maximum: 60 mg/day.Adult: 10 to 60 mg/day divided 2 to 3 times, preferably 30 to 45 minutes before meals. If the patient is unable to fall asleep due to taking the medicine late, the last dose should be taken before 6 pm. If no improvement in symptoms is seen after an appropriate dose adjustment for more than one month, the drug should be discontinued. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Anxiety & tension states, agitation, tics, tics in siblings, family history or diagnosis of Tourette's syndrome; glaucoma; hyperthyroidism; cardiac arrhythmias, severe angina pectoris. |
| Adverse Effects | Frequent: nervousness, insomnia, decreased appetite. Occasional: headache, drowsiness, dizziness, dry mouth, tachycardia, palpitations, arrhythmias, changes in BP & heart rate; GI disturbances, skin reactions, fever, arthralgia. Rare: blurred vision, moderately reduced weight gain & minor growth retardation in children. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% ), Loss of appetite (5% ), Nausea (12% ), Vomiting (10% ) Neurologic: Headache, Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% ), Nasopharyngitis (5%) |
| Pregnancy | Human Data Suggest Risk in 3rd Trimester |
| Lactation | No (Limited) Human Data - Potential Toxicity |
| More Info | UpToDate |
| TAH Drug Code | OMTD22 |
|---|---|
| Indications | Treatment for Attention Deficit Hyperactivity Disorder (ADHD) |
| Dosing | Take once daily, within 20 minutes after breakfast, with water. Do not chew, split, or crush the capsules. For patients not previously taking Methylphenidate or other stimulants: 22mg/day. If the desired effect is not achieved: increase dose by 11mg every 7 days (max 44mg/day). |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to methylphenidate or other components of the product, Marked agitation, anxiety, and tension; may aggravate symptoms, Glaucoma, Motor tics, Concomitant use of MAOIs, or use within 14 days of MAOI discontinuation, Family history or diagnosis of Tourette syndrome, Fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency; contains sucrose. |
| Adverse Effects | Common: Tachycardia (4.8-7%), Diaphoresis (Adult, 5.1%), Weight decreased (2.4-12%), Abdominal pain (Pediatric 4-15%), Decrease in appetite (2-35%), Loss of appetite (Adult 1.7% ; pediatric 3.1-9% or greater ), Nausea (2.4-12.8%), Vomiting (1.7-9%), Xerostomia (3-14%), Dizziness (Adult 6.7%; pediatric 1.9-3%), Headache (Adult 22.2% ; pediatric 2.4-19%), Insomnia (2.8-41%), Anxiety (Adult 8.2%), Depression (Adult 1.7-3.9%), Irritability (5.8-10%). Serious: Myocardial infarction, Raynaud's phenomenon, Sudden cardiac death, Decreased body growth, Gastrointestinal obstruction, With preexisting severe gastrointestinal narrowing and use of controlled-release formulations, Abnormal liver function, Cerebral artery occlusion, Cerebral hemorrhage, Cerebrovascular accident, Lowered convulsive threshold, Seizure, Blurred vision (>1.7-2%), Aggressive behavior (1.7-2.4%), Mania, Psychotic disorder, Priapism, Drug abuse, Substance dependence. |
| Pregnancy | Human Data Suggest Risk in 3rd Trimester |
| Lactation | No (Limited) Human Data - Potential Toxicity |
| More Info | UpToDate |
| TAH Drug Code | OMTD33 |
|---|---|
| Indications | Treatment for Attention Deficit Hyperactivity Disorder (ADHD) |
| Dosing | Take once daily, within 20 minutes after breakfast, with water. Do not chew, split, or crush the capsules. For patients not previously taking Methylphenidate or other stimulants: 22mg/day. If the desired effect is not achieved: increase dose by 11mg every 7 days (max 44mg/day). |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to methylphenidate or other components of the product. Marked agitation. anxiety. and tension; may aggravate symptoms. Glaucoma. Motor tics. Concomitant use of MAOIs, or use within 14 days of MAOI discontinuation. Family history or diagnosis of Tourette syndrome. Fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency; contains sucrose. |
| Adverse Effects | Common: Tachycardia (4.8-7%), Diaphoresis (Adult, 5.1%), Weight decreased (2.4-12%), Abdominal pain (Pediatric, 4-15%), Decrease in appetite (2-35%), Loss of appetite (Adult, 1.7% ; pediatric, 3.1-9% or greater), Nausea (2.4-12.8%), Vomiting (1.7-9%), Xerostomia (3-14%), Dizziness (Adult, 6.7%; pediatric, 1.9-3% .), Headache (Adult, 22.2% ; pediatric, 2.4-19%), Insomnia (2.8-41%), Anxiety (Adult, 8.2%), Depression (Adult, 1.7-3.9%), Irritability (5.8-10%). Serious: Myocardial infarction, Peripheral vascular disease, Raynaud's phenomenon, Sudden cardiac death, Decreased body growth, Gastrointestinal obstruction, With preexisting severe gastrointestinal narrowing and use of controlled-release formulations, Abnormal liver function, Cerebral artery occlusion, Cerebral hemorrhage, Cerebrovascular accident, Gilles de la Tourette's syndrome, Worsening, Lowered convulsive threshold, Seizure, Tic (Pediatric, 1-9%), Angle-closure glaucoma, Blurred vision (1.7-2% or greater), Raised intraocular pressure, Aggressive behavior (1.7-2.4%), Mania, Psychotic disorder, Priapism, Drug abuse, Substance dependence. |
| Pregnancy | Human Data Suggest Risk in 3rd Trimester |
| Lactation | No (Limited) Human Data - Potential Toxicity |
| More Info | UpToDate |
| TAH Drug Code | ORIT2 |
|---|---|
| Indications | Attention-deficit hyperactivity disorder; narcolepsy. |
| Dosing | Children >= 6 years (immediate-release Tablets) Initially 10mg. Dose adjustment can be based on the observed tolerance and therapeutic effect with gradual increments of 10 mg weekly. maximum: 40 mg/day. Adult: 20 mg QD initially.maximum: 60 mg/day.Ritalin LA sustained action capsules can be adjusted by increasing the dosage by 10 mg weekly. Immediate-release Tablets convert to extended-release Tablets: 5mg methylphenidate BID (immediate-release TABlets) is equivalent to 10mg methylphenidate(extended release Tablets) QD.10mg methylphenidate BID (immediate-release Tablets) is equivalent to 20mg methylphenidate(extended release Tablets) QD. 15mg methylphenidate BID (immediate-release TABlets) is equivalent to 30mg methylphenidate(extended release Tablets) QD. 20mg methylphenidate BID (immediate-release Tablets) is equivalent to 40mg methylphenidate(extended release Tablets) QD. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Anxiety & tension states, agitation, tics, tics in siblings, family history or diagnosis of Tourette's syndrome; glaucoma; hyperthyroidism; cardiac arrhythmias, severe angina pectoris. |
| Adverse Effects | Common: Tachycardia (4.8-7%), Diaphoresis (Adult, 5.1%), Weight decreased (2.4-12%), Abdominal pain (Pediatric, 4-15%), Decrease in appetite (2-35%), Loss of appetite (Adult, 1.7% ; pediatric, 3.1-9% or greater ), Nausea (2.4-12.8%), Vomiting (1.7-9%), Xerostomia (3-14%), Dizziness (Adult, 6.7%; pediatric, 1.9-3% .), Headache (Adult, 22.2% ; pediatric, 2.4-19%), Insomnia (2.8-41%), Anxiety (Adult, 8.2%), Depression (Adult, 1.7-3.9%), Irritability (5.8-10%) Serious: Myocardial infarction, Peripheral vascular disease, Raynaud's phenomenon, Sudden cardiac death, Decreased body growth, Gastrointestinal obstruction, With preexisting severe gastrointestinal narrowing and use of controlled-release formulations, Abnormal liver function, Cerebral artery occlusion, Cerebral hemorrhage, Cerebrovascular accident, Gilles de la Tourette's syndrome, Worsening, Lowered convulsive threshold, Seizure, Tic (Pediatric, 1-9%), Angle-closure glaucoma, Blurred vision (1.7-2% or greater ), Raised intraocular pressure, Aggressive behavior (1.7-2.4%), Mania, Psychotic disorder, Priapism, Drug abuse, Substance dependence |
| Pregnancy | Human Data Suggest Risk in 3rd Trimester |
| Lactation | No (Limited) Human Data - Potential Toxicity |
| More Info | UpToDate |
| TAH Drug Code | OTON36 |
|---|---|
| Indications | For treatment of attention deficit hyperactivity disorder. |
| Dosing | Initial and Dosage Range Recommendations for First-time Users: - Children (6-12 years): 18 mg/day; dosage range is 18-54 mg/day. - Adolescents (13-17 years): 18 mg/day; dosage range is 18-54 mg/day (do not exceed 2 mg/kg/day). - Adults (18-65 years): 18 or 36 mg/day; dosage range is 18-54 mg/day. For Patients Currently Using Methylphenidate: Patients currently taking Methylphenidate 10-60 mg/day, two or three times a day, should transition to Methylphenidate doses based on current regimens and clinical judgment. The maximum recommended daily dose is 54 mg. The converted dose should not exceed 54 mg/day. Previous Methylphenidate Daily Dose: Initial Dose of Methylphenidate 5 mg twice or three times daily: 18 mg every morning 10 mg twice or three times daily: 36 mg every morning 15 mg twice or three times daily: 54 mg every morning 20 mg twice or three times daily: 54 mg every morning |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to methylphenidate or other components of the product. Concomitant use of MAOIs, or use within 14 days of MAOI discontinuation. Patients who are markedly anxious, tense, or agitated. Patients with glaucoma. Patients with motor tics or a family history of Tourette’s syndrome. |
| Adverse Effects | Common: Tachycardia (4.8-7%), Diaphoresis (Adult, 5.1%), Weight decreased (2.4-12%), Abdominal pain (Pediatric, 4-15%), Decrease in appetite (2-35%), Loss of appetite (Adult, 1.7% ; pediatric, 3.1-9% or greater), Nausea (2.4-12.8%), Vomiting (1.7-9%), Xerostomia (3-14%), Dizziness (Adult, 6.7%; pediatric, 1.9-3% .), Headache (Adult, 22.2% ; pediatric, 2.4-19%), Insomnia (2.8-41%), Anxiety (Adult, 8.2%), Depression (Adult, 1.7-3.9%), Irritability (5.8-10%). Serious: Myocardial infarction, Peripheral vascular disease, Raynaud's phenomenon, Sudden cardiac death, Decreased body growth, Gastrointestinal obstruction, With preexisting severe gastrointestinal narrowing and use of controlled-release formulations, Abnormal liver function, Cerebral artery occlusion, Cerebral hemorrhage, Cerebrovascular accident, Gilles de la Tourette's syndrome, Worsening, Lowered convulsive threshold, Seizure, Tic (Pediatric, 1-9%), Angle-closure glaucoma, Blurred vision (1.7-2% or greater), Raised intraocular pressure, Aggressive behavior (1.7-2.4%), Mania, Psychotic disorder, Priapism, Drug abuse, Substance dependence. |
| Pregnancy | Human Data Suggest Risk in 3rd Trimester |
| Lactation | No (Limited) Human Data - Potential Toxicity |
| More Info | UpToDate |